Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter October 15, 2015

Ras Transformation Overrides a Proliferation Defect Induced by Tpm3.1 Knockout

  • Jason D. Coombes , Galina Schevzov , Chin-Yi Kan , Carlotta Petti , Michelle F. Maritz , Shane Whittaker , Karen L. Mackenzie and Peter W. Gunning EMAIL logo

Abstract

Extensive re-organisation of the actin cytoskeleton and changes in the expression of its binding proteins is a characteristic feature of cancer cells. Previously we have shown that the tropomyosin isoform Tpm3.1, an integral component of the actin cytoskeleton in tumor cells, is required for tumor cell survival. Our objective was to determine whether cancer cells devoid of Tpm3.1 would evade the tumorgenic effects induced by H-Ras transformation. The tropomyosin isoform (Tpm) expression profile of a range of cancer cell lines (21) demonstrates that Tpm3.1 is one of the most broadly expressed Tpm isoform. Consequently, the contribution of Tpm3.1 to the transformation process was functionally evaluated. Primary embryonic fibroblasts isolated from wild type (WT) and Tpm3.1 knockout (KO) mice were transduced with retroviral vectors expressing SV40 large T antigen and an oncogenic allele of the H-Ras gene, H-RasV12, to generate immortalized and transformed WT and KO MEFs respectively. We show that Tpm3.1 is required for growth factor-independent proliferation in the SV40 large T antigen immortalized MEFs, but this requirement is overcome by H-Ras transformation. Consistent with those findings, we found that Tpm3.1 was not required for anchorage independent growth or growth of H-Ras-driven tumors in a mouse model. Finally, we show that pERK and Importin 7 protein interactions are significantly decreased in the SV40 large T antigen immortalized KO MEFs but not in the H-Ras transformed KO cells, relative to control MEFs. The data demonstrate that H-Ras transformation overrides a requirement for Tpm3.1 in growth factor-independent proliferation of immortalized MEFs. We propose that in the SV40 large T antigen immortalized MEFs, Tpm3.1 is partly responsible for the efficient interaction between pERK and Imp7 resulting in cell proliferation, but this is overidden by Ras transformation.

References

1. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100 (2000) 57-70.Search in Google Scholar

2. Yamaguchi, H. and Condeelis, J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim. Biophys. Acta 1773 (2007) 642-652.Search in Google Scholar

3. Stehn, J.R., Schevzov, G., O'Neill, G.M. and Gunning, P.W. Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. Curr. Cancer Drug Targets 6 (2006) 245-256.Search in Google Scholar

4. Stevenson, R.P., Veltman, D. and Machesky, L.M. Actin-bundling proteins in cancer progression at a glance. J. Cell Sci. 125 (2012) 1073-1079.Search in Google Scholar

5. Rao, J. and Li, N. Microfilament actin remodeling as a potential target for cancer drug development. Curr. Cancer Drug Targets 4 (2004) 345-354.Search in Google Scholar

6. Gunning, P., O'Neill, G. and Hardeman, E. Tropomyosin-based regulation of the actin cytoskeleton in time and space. Physiol. Rev. 88 (2008) 1-35.Search in Google Scholar

7. Bryce, N.S., Schevzov, G., Ferguson, V., Percival, J.M., Lin, J.J., Matsumura, F., Bamburg, J.R., Jeffrey, P.L., Hardeman, E.C., Gunning, P. and Weinberger, R.P. Specification of actin filament function and molecular composition by tropomyosin isoforms. Mol. Biol. Cell 14 (2003) 1002-1016.Search in Google Scholar

8. Coulton, A.T., East, D.A., Galinska-Rakoczy, A., Lehman, W. and Mulvihill, D.P. The recruitment of acetylated and unacetylated tropomyosin to distinct actin polymers permits the discrete regulation of specific myosins in fission yeast. J. Cell Sci. 123 (2010) 3235-3243.Search in Google Scholar

9. Creed, S.J., Desouza, M., Bamburg, J.R., Gunning, P. and Stehn, J. Tropomyosin isoform 3 promotes the formation of filopodia by regulating the recruitment of actin-binding proteins to actin filaments. Exp. Cell Res. 317 (2011) 249-261.Search in Google Scholar

10. McMichael, B.K., Kotadiya, P., Singh, T., Holliday, L.S. and Lee, B.S. Tropomyosin isoforms localize to distinct microfilament populations in osteoclasts. Bone 39 (2006) 694-705. Search in Google Scholar

11. Schevzov, G., Bryce, N.S., Almonte-Baldonado, R., Joya, J., Lin, J.J., Hardeman, E., Weinberger, R. and Gunning, P. Specific features of neuronal size and shape are regulated by tropomyosin isoforms. Mol. Biol. Cell 16 (2005) 3425-3437.Search in Google Scholar

12. Yamashiro, S., Gokhin, D.S., Sui, Z., Bergeron, S.E., Rubenstein, P.A. and Fowler, V.M. Differential actin-regulatory activities of Tropomodulin1 and Tropomodulin3 with diverse tropomyosin and actin isoforms. J. Biol. Chem. 289 (2014) 11616-11629.Search in Google Scholar

13. Chhabra, E.S. and Higgs, H.N. The many faces of actin: matching assembly factors with cellular structures. Nat. Cell. Biol. 9 (2007) 1110-1121.Search in Google Scholar

14. Geeves, M.A., Hitchcock-DeGregori, S.E. and Gunning, P.W. A systematic nomenclature for mammalian tropomyosin isoforms. J. Muscle Res. Cell. Motil. 36 2014) 147-153.10.1007/s10974-014-9389-6Search in Google Scholar

15. Stehn, J.R., Haass, N.K., Bonello, T., Desouza, M., Kottyan, G., Treutlein, H., Zeng, J., Nascimento, P.R., Sequeira, V.B., Butler, T.L., Allanson, M., Fath, T., Hill, T.A., McCluskey, A., Schevzov, G., Palmer, S.J., Hardeman, E.C., Winlaw, D., Reeve, V.E., Dixon, I., Weninger, W., Cripe, T.P. and Gunning, P.W. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res. 73 (2013) 5169-5182.Search in Google Scholar

16. Helfman, D.M., Flynn, P., Khan, P. and Saeed, A. Tropomyosin as a regulator of cancer cell transformation. Adv. Exp. Med. Biol. 644 (2008) 124-131.Search in Google Scholar

17. Chow, S.N., Chen, R.J., Chen, C.H., Chang, T.C., Chen, L.C., Lee, W.J., Shen, J. and Chow, L.P. Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology. Eur. J. Gynaecol. Oncol. 31 (2010) 55-62.Search in Google Scholar

18. Tao, T., Shi, Y., Han, D., Luan, W., Qian, J., Zhang, J., Wang, Y. and You, Y. TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas. Tumour Biol. 35 (2014) 9053-9059.Search in Google Scholar

19. Gimona, M., Kazzaz, J.A. and Helfman, D.M. Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9618-9623.Search in Google Scholar

20. Raval, G.N., Bharadwaj, S., Levine, E.A., Willingham, M.C., Geary, R.L., Kute, T. and Prasad, G.L. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 22 (2003) 6194-6203.Search in Google Scholar

21. Shields, J.M., Mehta, H., Pruitt, K. and Der, C.J. Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin. Mol. Cell Biol. 22 (2002) 2304-2317.Search in Google Scholar

22. Yager, M.L., Hughes, J.A., Lovicu, F.J., Gunning, P.W., Weinberger, R.P. and O'Neill, G.M. Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma. Br. J. Cancer 89 (2003) 860-863. 10.1038/sj.bjc.6601201Search in Google Scholar

23. Shah, V., Bharadwaj, S., Kaibuchi, K. and Prasad, G.L. Cytoskeletal organization in tropomyosin-mediated reversion of ras-transformation: Evidence for Rho kinase pathway. Oncogene 20 (2001) 2112-2121.Search in Google Scholar

24. Hook, J., Lemckert, F., Schevzov, G., Fath, T. and Gunning, P. Functional identity of the gamma tropomyosin gene: Implications for embryonic development, reproduction and cell viability. Bioarchitecture 1 (2011) 49-59.Search in Google Scholar

25. Percival, J.M., Thomas, G., Cock, T.A., Gardiner, E.M., Jeffrey, P.L., Lin, J.J., Weinberger, R.P. and Gunning, P. Sorting of tropomyosin isoforms in synchronised NIH 3T3 fibroblasts: evidence for distinct microfilament populations. Cell Motil. Cytoskel. 47 (2000) 189-208.10.1002/1097-0169(200011)47:3<189::AID-CM3>3.0.CO;2-CSearch in Google Scholar

26. Schevzov G., Kee, A.J., Wang, B., Sequeira, V.B., Hook, J., Coombes, J.D., Lucas, C.A., Stehn J.R., Musgrove E.A., Cretu A., Assoian R., Fath T., Hanoch T., Seger R., Pleines, I., Kile, B.T., Hardeman, E.C. and Gunning, P.W. Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments. Mol. Biol. Cell. 26 (2015) 2475-2490.Search in Google Scholar

27. Choi, H.S., Yim, S.H., Xu, H.D., Jung, S.H., Shin, S.H., Hu, H.J., Jung, C.K., Choi, J.Y. and Chung, Y.J. Tropomyosin3 overexpression and a potential link to epithelial-mesenchymal transition in human hepatocellular carcinoma. BMC Cancer 10 (2010) 122.Search in Google Scholar

28. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22.Search in Google Scholar

29. Bos, J.L. ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689.Search in Google Scholar

30. Cox, A.D. and Der, C.J. Ras family signaling: therapeutic targeting. Cancer Biol. Ther. 1 (2002) 599-606.10.4161/cbt.306Search in Google Scholar

31. Roberts, P.J. and Der, C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310. Search in Google Scholar

32. Keshet, Y. and Seger, R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol. Biol. 661 (2010) 3-38.Search in Google Scholar

33. Chuderland, D., Konson, A. and Seger, R. Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol. Cell 31 (2008) 850-861.Search in Google Scholar

34. Plotnikov, A., Flores, K., Maik-Rachline, G., Zehorai, E., Kapri-Pardes, E., Berti, D.A., Hanoch, T., Besser, M.J. and Seger, R. The nuclear translocation of ERK1/2 as an anticancer target. Nat. Commun. 6 (2015) 6685.Search in Google Scholar

35. Vlahovich, N., Kee, A.J., Van der Poel, C., Kettle, E., Hernandez-Deviez, D., Lucas, C., Lynch, G.S., Parton, R.G., Gunning, P.W. and Hardeman, E.C. Cytoskeletal tropomyosin Tm5NM1 is required for normal excitationcontraction coupling in skeletal muscle. Mol. Biol. Cell 20 (2009) 400-409.Search in Google Scholar

36. Schevzov, G., Vrhovski, B., Bryce, N.S., Elmir, S., Qiu, M.R., O'Neill, G.M., Yang, N., Verrills, N.M., Kavallaris, M. and Gunning, P.W. Tissue-specific Tropomyosin Isoform Composition. J. Histochem. Cytochem. 53 (2005) 557-570.10.1369/jhc.4A6505.2005Search in Google Scholar

37. Land, H., Parada, L.F. and Weinberg, R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304 (1983) 596-602.Search in Google Scholar

38. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W. and Weinberg, R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468.Search in Google Scholar

39. Taylor, L.M., James, A., Schuller, C.E., Brce, J., Lock, R.B. and Mackenzie, K.L. Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human MRC5 fibroblasts that overcome a telomere-independent crisis during immortalization. J. Biol. Chem. 279 (2004) 43634-43645.Search in Google Scholar

40. Novy, R.E., Sellers, J.R., Liu, L.F. and Lin, J.J. In vitro functional characterization of bacterially expressed human fibroblast tropomyosin isoforms and their chimeric mutants. Cell Motil. Cytoskel. 26 (1993) 248-261.Search in Google Scholar

41. Hannan, A.J., Gunning, P., Jeffrey, P.L. and Weinberger, R.P. Structural compartments within neurons: developmentally regulated organization of microfilament isoform mRNA and protein. Mol. Cell. Neurosci. 11 (1998) 289-304.Search in Google Scholar

42. Hanahan, D. and Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144 (2011) 646-674.Search in Google Scholar

43. Button, E., Shapland, C. and Lawson, D. Actin, its associated proteins and metastasis. Cell Motil. Cytoskel. 30 (1995) 247-251.10.1002/cm.970300402Search in Google Scholar

44. Pawlak, G. and Helfman, D.M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr. Opin. Genet. Dev. 11 (2001) 41-47.Search in Google Scholar

45. Kharitonova, M.A., Kopnin, P.B. and Vasiliev, J.M. Transformation by RAS oncogene decreases the width of substrate-spread fibroblasts but not their length. Cell Biol. Int. 31 (2007) 220-223.Search in Google Scholar

46. Temm-Grove, C.J., Jockusch, B.M., Weinberger, R.P., Schevzov, G. and Helfman, D.M. Distinct localizations of tropomyosin isoforms in LLC-PK1 epithelial cells suggests specialized function at cell-cell adhesions. Cell Motil. Cytoskel. 40 (1998) 393-407.Search in Google Scholar

47. Caldwell, B.J., Lucas, C., Kee, A.J., Gaus, K., Gunning, P.W., Hardeman, E.C., Yap, A.S. and Gomez, G.A. Tropomyosin isoforms support actomyosin biogenesis to generate contractile tension at the epithelial zonula adherens. Cytoskeleton (Hoboken, N.J.) 71 (2014) 663-676.Search in Google Scholar

48. Haroon, Z.A., Amin, K., Lichtlen, P., Sato, B., Huynh, N.T., Wang, Z., Schaffner, W. and Murphy, B.J. Loss of metal transcription factor-1 suppresses tumor growth through enhanced matrix deposition. FASEB J. 18 (2004) 1176-1184.Search in Google Scholar

49. Vrhovski, B., Lemckert, F. and Gunning, P. Modification of the tropomyosin isoform composition of actin filaments in the brain by deletion of an alternatively spliced exon. Neuropharmacology 47 (2004) 684-693. Search in Google Scholar

50. Fath, T., Agnes Chan, Y.K., Vrhovski, B., Clarke, H., Curthoys, N., Hook, J., Lemckert, F., Schevzov, G., Tam, P., Watson, C.M., Khoo, P.L. and Gunning, P. New aspects of tropomyosin-regulated neuritogenesis revealed by the deletion of Tm5NM1 and 2. Eur. J. Cell Biol. 89 (2010) 489-498.Search in Google Scholar

51. Schwartz, M.A. and Assoian, R.K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J. Cell Sci. 114 (2001) 2553-2560.Search in Google Scholar

52. Weber, J.D., Raben, D.M., Phillips, P.J. and Baldassare, J.J. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 326 (1997) 61-68.Search in Google Scholar

53. Soderberg, O., Gullberg, M., Jarvius, M., Ridderstrale, K., Leuchowius, K.J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.G. and Landegren, U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3 (2006) 995-1000. Search in Google Scholar

Received: 2015-5-28
Accepted: 2015-7-30
Published Online: 2015-10-15
Published in Print: 2015-12-1

© 2015

Downloaded on 20.5.2024 from https://www.degruyter.com/document/doi/10.1515/cmble-2015-0037/html
Scroll to top button